D 22888

Drug Profile

D 22888

Latest Information Update: 11 Dec 1997

Price : $50

At a glance

  • Originator elbion
  • Class Antiasthmatics
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 11 Dec 1997 Discontinued-Preclinical for Asthma in Germany (Unknown route)
  • 15 Sep 1997 A preclinical study has been added to the pharmacodynamics section
  • 29 Aug 1996 Preclinical development for Asthma in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top